Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prophylactic Meropenem in Severe Acute Necrotizing Pancreatitis
NCT00061438Phase 4Completed
- Sponsor
- Pfizer
- Start
- Feb 2003
- Primary completion
- Dec 2004
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 4, randomised, double-blind trial in acute necrotizing pancreatitis (ANP) comparing Meropenem with Placebo (2 arms). Primary endpoint: Development of pancreatic or peripancreatic infection at 42 days. Started Feb 2003; status: completed.
02
Drugs
meropenem
03
Conditions
acute necrotizing pancreatitis (ANP)
Beyond the preview
Go deeper on NCT00061438.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061438.